Xiaobin Ma
Overview
Explore the profile of Xiaobin Ma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
708
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chang L, Liu D, Hao Q, Ren X, Liu P, Liu X, et al.
J Cancer Res Clin Oncol
. 2024 Jul;
150(8):378.
PMID: 39085623
Purpose: Many T1-2N0-1M0 triple-negative breast cancer (TNBC) patients who undergo neoadjuvant chemotherapy (NAC) do not receive breast-conserving therapy (BCT) due to concerns about non-pCR or lymph node metastasis presence. Methods:...
12.
Xu P, Luo W, Hu J, Ma X, Hao Q, Hui W, et al.
Cancer Med
. 2024 Jun;
13(11):e7244.
PMID: 38859692
Purpose: To assess the efficacy of neoadjuvant endocrine therapy in female HR-positive/HER2-negative breast cancer patients. Data And Methods: We identified female patients aged ≥18 years with cT1-4N0-XM0, HR(+), and HER2(-)...
13.
Chen X, Wei X, Yao P, Liu Y, Guan H, Kang H, et al.
Clin Breast Cancer
. 2024 Apr;
24(4):e195-e202.
PMID: 38670862
Background: The combination of neoadjuvant chemotherapy and anti-angiogenesis therapy for patients with triple-negative breast cancer (TNBC) remains inadequately supported by evidence. We conducted a single-arm, open-label, multicenter, phase II trial...
14.
Chang L, Liu D, Zhao X, Dai L, Ren X, Hao Q, et al.
Clin Transl Oncol
. 2024 Apr;
26(9):2323-2338.
PMID: 38592638
Introduction: Neoadjuvant systemic therapy (NAST) is vital in the management of HER2-positive (HER2+) breast cancer. Nevertheless, the indications for NAST in tumors <2 cm remain controversial. Method: A total of...
15.
Dai L, Yan W, Ren X, Liu D, Chang L, Lin S, et al.
Clin Breast Cancer
. 2024 Mar;
24(4):351-362.
PMID: 38521702
Background: Currently, research on the prognostic factors of unilateral breast cancer (UBC) patients receiving contralateral prophylactic mastectomy (CPM) is limited. This study aimed to construct a new nomogram to predict...
16.
Li S, Meng C, Hao Q, Zhou R, Dai L, Guo Y, et al.
Biomaterials
. 2024 Mar;
307:122537.
PMID: 38492523
Non-small cell lung cancer (NSCLC) brain metastases present a significant treatment challenge due to limited drug delivery efficiency and severe adverse reactions. In this study, we address these challenges by...
17.
Ren X, Cui H, Dai L, Chang L, Liu D, Yan W, et al.
J Cancer Res Clin Oncol
. 2024 Mar;
150(3):119.
PMID: 38466449
Purpose: Gene mutations drive tumor immune microenvironment (TIME) heterogeneity, in turn affecting prognosis and immunotherapy efficacy. PIK3CA is the most frequently mutated gene in breast cancer (BC), yet its relevance...
18.
Liu D, Chang L, Zhao X, Dai L, Cui H, Liu P, et al.
Clin Breast Cancer
. 2024 Feb;
24(4):e232-e243.e1.
PMID: 38368246
Introduction: The survival benefit of axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB) combined with radiation, and ALND combined with radiation remains unclear in breast cancer (BC) patients...
19.
Deng Y, Hou Z, Li Y, Yi M, Wu Y, Zheng Y, et al.
Cell Commun Signal
. 2024 Feb;
22(1):115.
PMID: 38347536
Phosphorylation proteomics is the basis for the study of abnormally activated kinase signaling pathways in breast cancer, which facilitates the discovery of new oncogenic agents and drives the discovery of...
20.
Guo X, Tang X, Zhang M, Ma X, Wang J, Liang H
Water Res
. 2023 Dec;
250:121038.
PMID: 38157600
The application of magnetic fields (MFs) and magnetic particles (MPs) in water treatment has attracted widespread attention due to their stability, strong biological compatibility, and less chemical consumption. This study...